Third Quarter 2026 Interim Management Statement

Strong third quarter delivery with continued revenue momentum across the Group FY26 adjusted EPS1 upgraded

4 November 2026 – Glanbia plc, the Better Nutrition company (“Glanbia” or the “Group”), is issuing its Interim Management Statement for the nine-month period ended 3 October 2026 (“the period” or “YTD 2026”).

YTD 2026 Highlights1

  • Group like-for-like (“LFL”) revenue growth of 9.9% with volume growth across all three segments;
  • Performance Nutrition (“PN”) LFL revenue growth of 18.0%;
  • Optimum Nutrition LFL revenue growth of 25.8% driven by strong category growth, market share gains, new distribution, continued innovation and pricing actions;
    • Q3 Optimum Nutrition LFL revenue growth of 26.9% (+0.8% volume; +26.1% price);
  • Health & Nutrition (“H&N”) LFL revenue growth of 9.8% with volume growth of 11.5% driven by strong demand across priority end-use markets;
  • Dairy Nutrition (“DN”) LFL revenue growth of 2.1% with volume and pricing growth in protein solutions; and
  • Wendy Chang Smith appointed CFO Designate, effective as CFO and Executive Director from 31 March 2027.

FY 2026 Outlook:

  • Following a strong performance in the first nine months of the year, Glanbia now expects to deliver:
    • PN LFL revenue growth of 16% to 17% (previously 12% to 14%);
    • DN EBITDA $175-180 million (previously $170-180 million); and
    • Adjusted EPS growth of 22% to 24% constant currency (previously 17% to 20%).
  • All other guidance remains unchanged.

Commenting today, Hugh McGuire, Chief Executive Officer, said:

“I am pleased to report that Glanbia delivered a strong performance in the first nine months of the year, delivering Group like-for-like revenue growth of 9.9%, with volume growth across all three segments. 

Our Performance Nutrition segment delivered a strong year-to-date performance, with Optimum Nutrition achieving like-for-like revenue growth of 25.8%. This was driven by continued market share gains, expanded distribution, innovation and pricing actions in response to significant whey inflation, supported by our continued brand investment. 

We also generated volume growth across Health & Nutrition and Dairy Nutrition, with good demand in H&N’s end-use markets and strong pricing growth in protein solutions within DN. 

With a market-leading portfolio of better nutrition brands and ingredients, Glanbia is uniquely positioned to capitalise on favourable category dynamics and sustained consumer demand for our products. We are upgrading our full year adjusted EPS growth to a range of 22% to 24% which will be driven by a strong performance across all three segments.”

1. Like-for-like revenue growth excludes the net impact from acquisitions and disposals and is shown on a constant currency basis. All changes are shown on a constant currency basis for the nine-months to 3 October 2026 unless otherwise stated.  
2. Consumption growth is US measured channels and includes online, FDMC (Food, Drug, Mass, Club) and specialty channels. Data compiled from published external sources and Glanbia estimates for the 13 week period to 3 October 2026.

Back to Press releases